What is Candel Therapeutics?
Candel Therapeutics is a clinical-stage biopharmaceutical company focused on the development of viral immunotherapies. Its core technology is designed to induce in situ vaccination, a process that triggers the immune system to recognize and attack tumor cells by presenting unique antigens and neoantigens. By stimulating both innate and adaptive immune mechanisms, the company aims to generate a systemic, durable T-cell response that targets both primary tumors and distant metastases. This individualized approach to cancer treatment represents a paradigm shift in immunotherapy, offering the potential to improve patient outcomes across a diverse range of oncological indications.
How much funding has Candel Therapeutics raised?
Candel Therapeutics has raised a total of $195.4M across 4 funding rounds:
Series A
$14.2M
Series B
$28.7M
Series C
$22.5M
Debt
$130M
Series A (2016): $14.2M with participation from National Securities Corporation
Series B (2019): $28.7M led by PBM Capital
Series C (2019): $22.5M, investors not publicly disclosed
Debt (2025): $130M featuring Trinity Capital
Key Investors in Candel Therapeutics
National Securities Corporation
A full-service wealth management firm providing comprehensive brokerage, investment management, and consultative financial advice to diverse client portfolios.
PBM Capital
An investment entity with a background in consumer-facing health products, now diversifying its portfolio into high-growth life sciences and medical innovation.
Trinity Capital
A specialized banking and financial services firm providing tailored lending and advisory solutions to support the growth of corporate entities.
What's next for Candel Therapeutics?
With the successful acquisition of this latest capital, Candel Therapeutics is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic focus will likely shift toward scaling manufacturing processes and advancing late-stage trials to validate the efficacy of its viral vectors. As the company moves deeper into its enterprise-level growth phase, the emphasis will remain on demonstrating the clinical utility of its T-cell activation platform. Investors will be closely monitoring the firm's ability to translate its innovative scientific methodology into tangible therapeutic breakthroughs, potentially setting the stage for future commercialization or strategic partnerships within the broader biotechnology landscape.
See full Candel Therapeutics company page
